For research use only. Not for therapeutic Use.
MHY 553 is a PPARα agonist that improved aged-induced hepatic steatosis, in part by increasing β-oxidation signaling and decreasing inflammation in the liver. Potential pharmaceutical agent for treating hepatic steatosis in aging.
Keywords: MHY 553 | supplier | PPARα agonist | NSC 33005 | MHY553 | MHY-553 | NSC33005 | NSC-33005 | CAS [6265-56-1] | Metabolism | PPAR | Agonist | Receptors | Hepatic steatosis
| Catalog Number | I047628 |
| CAS Number | 6265-56-1 |
| Molecular Formula | C13H9NO2S |
| Purity | ≥95% |
| IUPAC Name | 4-(1,3-benzothiazol-2-yl)benzene-1,3-diol |
| InChI | InChI=1S/C13H9NO2S/c15-8-5-6-9(11(16)7-8)13-14-10-3-1-2-4-12(10)17-13/h1-7,15-16H |
| SMILES | C1=CC=C2C(=C1)N=C(S2)C3=C(C=C(C=C3)O)O |
| Reference | SM Kim et al. Novel PPARa agonist MHY553 alleviates hepatic steatosis by increasing fatty acid oxidation and decreasing inflammation during aging. Oncotarget. 2017 Jul 11;8(28):46273-46285. |
